Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Triple Negative Breast Neoplasms 4 Carcinoma, Non-Small-Cell Lung 4 Small Cell Lung Carcinoma 2 Ovarian Neoplasms 2 Neoplasms 2 Melanoma 2 Lung Neoplasms 2 Endometrial Neoplasms 2 Breast Neoplasms 2 Bile Duct Neoplasms 2 Uterine Cervical Neoplasms 1 Thoracic Neoplasms 1 SCLC 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasms by Site 1 Neoplasm Metastasis 1 Lung Diseases 1 High Grade Serous Carcinoma 1 Hereditary Sensory and Autonomic Neuropathies 1 Fallopian Tube Neoplasms 1 Extensive Stage Small Cell Lung Cancer 1 Cholangiocarcinoma 1 Carcinosarcoma 1 Carcinoma, Transitional Cell 1

Interventions

Fulvestrant 8 olaparib 4 Capecitabine 4 pyrotinib 3 Docetaxel 3 toripalimab 2 Vinorelbine 2 Trastuzumab 2 Letrozole 2 Injections 2 Goserelin 2 Alpelisib 2 vandetanib 1 trastuzumab deruxtecan 1 talazoparib 1 sacituzumab govitecan 1 pembrolizumab 1 neratinib 1 liposomal doxorubicin 1 exemestane 1 eribulin 1 dalpiciclib 1 ceralasertib 1 cediranib 1 capivasertib 1 abemaciclib 1 Tablets 1 Paclitaxel 1 Moxifloxacin 1 Lead 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Breast Cancer × ceralasertib × Clear all

NCT03182634 2019-01-22

plasmaMATCH

Institute of Cancer Research, United Kingdom

Phase 2 Unknown

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡